- Home
- PINC vs BEAM Comparison
PINC vs BEAM Comparison
Compare PINC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINC
- BEAM
- Stock Information
- Founded
- PINC 2013
- BEAM 2017
- Country
- PINC United States
- BEAM United States
- Employees
- PINC N/A
- BEAM N/A
- Industry
- PINC Other Consumer Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PINC Consumer Discretionary
- BEAM Health Care
- Exchange
- PINC Nasdaq
- BEAM Nasdaq
- Market Cap
- PINC 1.9B
- BEAM 1.6B
- IPO Year
- PINC 2013
- BEAM 2020
- Fundamental
- Price
- PINC $22.01
- BEAM $20.01
- Analyst Decision
- PINC Hold
- BEAM Strong Buy
- Analyst Count
- PINC 6
- BEAM 11
- Target Price
- PINC $22.20
- BEAM $48.90
- AVG Volume (30 Days)
- PINC 2.4M
- BEAM 2.0M
- Earning Date
- PINC 08-19-2025
- BEAM 08-05-2025
- Dividend Yield
- PINC 3.82%
- BEAM N/A
- EPS Growth
- PINC N/A
- BEAM N/A
- EPS
- PINC 0.63
- BEAM N/A
- Revenue
- PINC $1,260,388,000.00
- BEAM $63,578,000.00
- Revenue This Year
- PINC N/A
- BEAM N/A
- Revenue Next Year
- PINC N/A
- BEAM $8.82
- P/E Ratio
- PINC $20.19
- BEAM N/A
- Revenue Growth
- PINC 7.16
- BEAM N/A
- 52 Week Low
- PINC $17.23
- BEAM $13.53
- 52 Week High
- PINC $23.56
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- PINC 47.12
- BEAM 68.31
- Support Level
- PINC $21.40
- BEAM $16.59
- Resistance Level
- PINC $22.06
- BEAM $17.38
- Average True Range (ATR)
- PINC 0.45
- BEAM 1.10
- MACD
- PINC -0.07
- BEAM 0.35
- Stochastic Oscillator
- PINC 45.86
- BEAM 89.70
About PINC Premier Inc.
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.